These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 23769978)

  • 21. Design, synthesis, and biological evaluation of 3-(1H-1,2,3-triazol-1-yl)benzamide derivatives as Potent Pan Bcr-Abl inhibitors including the threonine(315)→isoleucine(315) mutant.
    Li Y; Shen M; Zhang Z; Luo J; Pan X; Lu X; Long H; Wen D; Zhang F; Leng F; Li Y; Tu Z; Ren X; Ding K
    J Med Chem; 2012 Nov; 55(22):10033-46. PubMed ID: 23088644
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Berbamine: a novel inhibitor of bcr/abl fusion gene with potent anti-leukemia activity.
    Xu R; Dong Q; Yu Y; Zhao X; Gan X; Wu D; Lu Q; Xu X; Yu XF
    Leuk Res; 2006 Jan; 30(1):17-23. PubMed ID: 16023722
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors.
    Redaelli S; Mologni L; Rostagno R; Piazza R; Magistroni V; Ceccon M; Viltadi M; Flynn D; Gambacorti-Passerini C
    Am J Hematol; 2012 Nov; 87(11):E125-8. PubMed ID: 23044928
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The interplay of structural information and functional studies in kinase drug design: insights from BCR-Abl.
    Eck MJ; Manley PW
    Curr Opin Cell Biol; 2009 Apr; 21(2):288-95. PubMed ID: 19217274
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Backbone NMR resonance assignment of the Abelson kinase domain in complex with imatinib.
    Vajpai N; Strauss A; Fendrich G; Cowan-Jacob SW; Manley PW; Jahnke W; Grzesiek S
    Biomol NMR Assign; 2008 Jun; 2(1):41-2. PubMed ID: 19636920
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Resistance to targeted therapy in chronic myelogenous leukemia.
    Hochhaus A; Erben P; Ernst T; Mueller MC
    Semin Hematol; 2007 Jan; 44(1 Suppl 1):S15-24. PubMed ID: 17292737
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Design, synthesis and biological evaluation of novel acrylamide analogues as inhibitors of BCR-ABL kinase.
    Li S; Yao Z; Zhao Y; Chen W; Wang H; Kuang X; Zhan W; Yao S; Yu S; Hu W
    Bioorg Med Chem Lett; 2012 Aug; 22(16):5279-82. PubMed ID: 22789429
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Imatinib mesylate (STI571) abrogates the resistance to doxorubicin in human K562 chronic myeloid leukemia cells by inhibition of BCR/ABL kinase-mediated DNA repair.
    Majsterek I; Sliwinski T; Poplawski T; Pytel D; Kowalski M; Slupianek A; Skorski T; Blasiak J
    Mutat Res; 2006 Jan; 603(1):74-82. PubMed ID: 16388976
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants.
    Tokarski JS; Newitt JA; Chang CY; Cheng JD; Wittekind M; Kiefer SE; Kish K; Lee FY; Borzillerri R; Lombardo LJ; Xie D; Zhang Y; Klei HE
    Cancer Res; 2006 Jun; 66(11):5790-7. PubMed ID: 16740718
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin.
    Nimmanapalli R; O'Bryan E; Huang M; Bali P; Burnette PK; Loughran T; Tepperberg J; Jove R; Bhalla K
    Cancer Res; 2002 Oct; 62(20):5761-9. PubMed ID: 12384536
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.
    Fiskus W; Pranpat M; Balasis M; Bali P; Estrella V; Kumaraswamy S; Rao R; Rocha K; Herger B; Lee F; Richon V; Bhalla K
    Clin Cancer Res; 2006 Oct; 12(19):5869-78. PubMed ID: 17020995
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Crystal structure of the T315I Abl mutant in complex with the aurora kinases inhibitor PHA-739358.
    Modugno M; Casale E; Soncini C; Rosettani P; Colombo R; Lupi R; Rusconi L; Fancelli D; Carpinelli P; Cameron AD; Isacchi A; Moll J
    Cancer Res; 2007 Sep; 67(17):7987-90. PubMed ID: 17804707
    [TBL] [Abstract][Full Text] [Related]  

  • 33. BCR-ABL tyrosine kinase inhibitor pharmacophore model derived from a series of phenylaminopyrimidine-based (PAP) derivatives.
    Cui J; Fu R; Zhou LH; Chen SP; Li GW; Qian SX; Liu S
    Bioorg Med Chem Lett; 2013 Apr; 23(8):2442-50. PubMed ID: 23473682
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Kinase dynamics. Using ancient protein kinases to unravel a modern cancer drug's mechanism.
    Wilson C; Agafonov RV; Hoemberger M; Kutter S; Zorba A; Halpin J; Buosi V; Otten R; Waterman D; Theobald DL; Kern D
    Science; 2015 Feb; 347(6224):882-6. PubMed ID: 25700521
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New effective inhibitors of the Abelson kinase.
    Kraus GA; Gupta V; Mokhtarian M; Mehanovic S; Nilsen-Hamilton M
    Bioorg Med Chem; 2010 Sep; 18(17):6316-21. PubMed ID: 20674368
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Energetic dissection of Gleevec's selectivity toward human tyrosine kinases.
    Agafonov RV; Wilson C; Otten R; Buosi V; Kern D
    Nat Struct Mol Biol; 2014 Oct; 21(10):848-53. PubMed ID: 25218445
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Radotinib is an effective inhibitor of native and kinase domain-mutant BCR-ABL1.
    Zabriskie MS; Vellore NA; Gantz KC; Deininger MW; O'Hare T
    Leukemia; 2015 Sep; 29(9):1939-42. PubMed ID: 25676420
    [No Abstract]   [Full Text] [Related]  

  • 38. Allosteric Modulator Discovery: From Serendipity to Structure-Based Design.
    Lu S; He X; Ni D; Zhang J
    J Med Chem; 2019 Jul; 62(14):6405-6421. PubMed ID: 30817889
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Pharmacophore Network: A Computational Method for Exploring Structure-Activity Relationships from a Large Chemical Data Set.
    Métivier JP; Cuissart B; Bureau R; Lepailleur A
    J Med Chem; 2018 Apr; 61(8):3551-3564. PubMed ID: 29648816
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Photosensitization by imatinib. A photochemical and photobiological study of the drug and its substructures.
    Nardi G; Lhiaubet-Vallet V; Miranda MA
    Chem Res Toxicol; 2014 Nov; 27(11):1990-5. PubMed ID: 25275675
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.